论文部分内容阅读
1999年2月开始进行两项主要的人类免疫缺陷症病毒（HIV）疫苗的临床试验。尽管这两种疫苗是以不同的方式预防艾滋病,但它们都将答复一个问题,即美国和欧洲研制的疫苗能否有效抵抗非洲和亚洲的病毒株。Pasteur M(?)rieux Connaught公司在制成疫苗后数年,开始在非洲对疫苗进行首次试验。目前正在乌干达开展的这项Ⅰ期试验将包括40名HIV感染危险性低的HIV血清阴性的健康成人,将对该公司的ALVAC vCP205疫苗进行评价,该疫苗由3个插入减毒金丝雀痘病毒的HIV基因组成。
Two major clinical trials of human immunodeficiency virus (HIV) vaccine started in February 1999. Although both vaccines prevent AIDS in different ways, they all answer the question of whether vaccines developed in the United States and Europe are effective against the strains in Africa and Asia. Pasteur M (?) Rieux Connaught company in the vaccine a few years after the start of the vaccine in Africa for the first time. The Phase I trial currently underway in Uganda, which will include 40 HIV-seronegative healthy adults at low risk of HIV infection, will evaluate the company’s ALVAC vCP205 vaccine, which will consist of three vaccines that are inserted into the attenuated canary birdpox HIV gene composition of the virus.